Rise and shine, another busy day is on the way. There is a rhythm to such observations, since our short person is, once again, hunched over a laptop for remote learning and our official mascot is snoozing cozily in a corner. As for us, we are firing up the trusty coffee kettle for yet another cup of needed stimulation. Our choice today is cinnamon mocha. Please feel free to join us. Meanwhile, here is the latest grab bag of interesting items. We hope your day is productive and enjoyable. And keep us in mind for any saucy tidbits that float by. …

BioNTech (BNTX) disclosed that, along with its partner, Pfizer (PFE), it would increase manufacturing capacity of their Covid-19 vaccine to 2.5 billion doses by the end of 2021, unveiling for the first time projected sales of close to $11.73 billion from the product this year, Reuters writes. Pfizer previously said the companies would likely produce between 2.3 billion and 2.4 billion doses this year. As of last week, more than 200 million doses have been supplied, while signed orders for delivery in 2021 currently amount to 1.4 billion doses.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.


Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]